OR WAIT null SECS
November 16, 2026
Podcast
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.
November 12, 2026
TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.
Tom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.
November 07, 2026
Article
Compared to metformin, GLP-1 RAs were linked to more normoglycemia reversion and less diabetes progression in 256,492 adults with prediabetes.
October 29, 2026
Video
David Leehey, MD, says about half of the 2376 enrolled veterans were taking an SGLT2 inhibitor at baseline.
October 28, 2026
Retatrutide lowered A1C 2.2% vs 1.8% and cut weight 19.5%-20.9% vs 9.4% with semaglutide 2 mg at 80 weeks in adults with type 2 diabetes.
October 23, 2026
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
October 22, 2026
Phoom Narongkiatikhun, MD, discusses sleeve gastrectomy reducing LV mass, kidney volume, and albuminuria and boosting medullary FSOC in youth-onset T2D.
October 16, 2026
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a major breakthrough with the Twiist insulin pump and the recent ADA/EASD T2D guidelines.
October 07, 2026
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.